A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

被引：0
|
作者：
Basil F. El-Rayes
Mark M. Zalupski
Anthony F. Shields
Ann Marie Ferris
Ulka Vaishampayan
Lance K. Heilbrun
Raghu Venkatramanamoorthy
Volkan Adsay
Philip A. Philip
机构：
[1] Wayne State University,Karmanos Cancer Institute
[2] University of Michigan,undefined
来源：
Investigational New Drugs | 2005年 / 23卷
关键词：
pancreatic cancer; cisplatin; celecoxib; gemcitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to determine the effect of gemcitabine by fixed-dose rate infusion (FDR), cisplatin and the COX-2 inhibitor, celecoxib, on the 6-month survival rate in patients with metastatic pancreatic cancer.
引用
收藏
页码：583 / 590
页数：7
相关论文
共 50 条
  • [1] A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Ferris, AM
    Vaishampayan, U
    Heilbrun, LK
    Venkatramanamoorthy, R
    Adsay, V
    Philip, PA
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 583 - 590
  • [2] GEMCITABINE (GEM) PLUS CELECOXIB IN ADVANCED PANCREATIC CANCER: A PHASE II STUDY
    Valcamonico, F.
    Ferrari, V. D.
    Simoncini, E.
    Amoroso, V.
    Vassalli, L.
    Rangoni, G.
    Grisanti, S.
    Marpicati, P.
    Marini, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [3] Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Vaishampayan, U
    Heilbrun, LK
    Jain, V
    Adsay, V
    Day, J
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2920 - 2925
  • [4] Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Tiberio, GAM
    Nodari, F
    Strina, C
    Marini, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) : 185 - 190
  • [5] Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
    Lipton, Allan
    Campbell-Baird, Cynthia
    Witters, Lois
    Harvey, Harold
    Ali, Suhail
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2010, 44 (04) : 286 - 288
  • [6] Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
    Vittorio Ferrari
    Francesca Valcamonico
    Vito Amoroso
    Edda Simoncini
    Lucia Vassalli
    Patrizia Marpicati
    Giovanni Rangoni
    Salvatore Grisanti
    Guido AM Tiberio
    Franco Nodari
    Carla Strina
    Giovanni Marini
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 185 - 190
  • [7] Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer
    Novarino, A
    Chiappino, I
    Bertelli, GF
    Heouaine, A
    Ritorto, G
    Addeo, A
    Bellone, G
    Merlano, M
    Bertetto, O
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 474 - 477
  • [8] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [9] Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
    Brodowicz, T
    Wolfram, RM
    Köstler, WJ
    Tomek, S
    Vaclavik, I
    Steger, GG
    Teleky, B
    Függer, R
    Jakesz, R
    Zielinski, CC
    ANTI-CANCER DRUGS, 2000, 11 (08) : 623 - 628
  • [10] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
12345